Document is current
Any future updates will be listed below
-
Authors
Varadkar, Tanvi
Zhou, Zhuoxin Zora
Zhang, Jiashuai
Sarkar, Anusua
Du, Zhantao
Chowdhury, Srijita
Lim, Hwayeon
Zhou, Lufang
Liu, Xiaoguang Margaret
-
Funding
Funding for this research was provided by:
United States National Institutes of Health (R01CA262028)
United States National Institutes of Health (NIH) National Cancer Institute (1R01CA281980-01)
- License Information
-
More Information
Article History
Received: 7 June 2025
Accepted: 30 October 2025
First Online: 29 December 2025
Declarations
:
: The animal studies were conducted according to the Institutional Animal Care and Use Committee (IACUC) Protocol IACUC-2022A00000029, which was approved by the Institutional Biosafety Committee at the Ohio State University.
: All authors agree to be published.
: Patent in protection of the cmLumiOpto gene therapy and technology of mAb-Exo-AAV has been filed by The Ohio State University (U.S. Patent Serial No. 63/723,791 “Mitochondrial Optogenetics-Based Gene Therapies and Their Methods of Use”). Patent in protection of the anti-CD276 monoclonal antibody (PCT/US2024/037844 “Chimeric antibody compositions and methods of use thereof”) was licensed by BiFormyxBio. The corresponding author X. Margaret Liu serves as consultant with equity in BiFormyxBio. The authors declare no other competing interests.
